Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator

Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Read why LGND stock is a Buy.

Ligand Pharmaceuticals: The Bull Case Is A Biotech ARM, The Bear Case Is Just Another Royalty Trust

Ligand Pharma (LGND) stock jumped in the final week of June, but the proximate cause was the pricing of $625M of convertible ...
Le Lézard

Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight

Recently published Nephrotic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, nephrotic syndrome emerging drugs, market share of individual ...

Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX)

Detailed price information for Definium Therapeutics Inc (DFTX-Q) from The Globe and Mail including charting and trades.

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) ...